Michael Jarman

8.7k citations

225 papers · 7.0k indexed · h-index 46

Pharmacology top 0.2%
- Pharmacogenetics and Drug Metabolism 32
Genetics top 1%
- Estrogen and related hormone effects 61
Cancer Research top 2%
Toxicology top 1%
Pharmaceutical Science top 1%
- Chemical Reactions and Isotopes 22
Molecular Biology
- DNA and Nucleic Acid Chemistry 14
Oncology
- Cancer Treatment and Pharmacology 13
- Drug Transport and Resistance Mechanisms 12
Spectroscopy
- Analytical Chemistry and Chromatography 12
Endocrinology, Diabetes and Metabolism
- Hormonal and reproductive studies 12

Co-authors: A. B. Foster Martin Rowlands Gerard A. Potter S. Elaine Barrie Raymond McCague Mitch Dowsett R. Charles Coombes P.D. Lawley
Cited by: Pharmacology Genetics Cancer Research
Journals: Biochemical Pharmacology (33 papers)Journal of Medicinal Chemistry (23 papers)British Journal of Cancer (9 papers)
Partner nations: United Kingdom United States Poland

In The Last Decade

Michael Jarman

221 papers receiving 6.5k citations

Peers

Countries citing papers authored by Michael Jarman

Since Specialization

Citations

This map shows the geographic impact of Michael Jarman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Jarman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Jarman more than expected).

Fields of papers citing papers by Michael Jarman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Jarman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Jarman. The network helps show where Michael Jarman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael Jarman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Jarman Line = papers co-authored together Michael Jarman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Exercise-induced inflammatory and metabolic adaptations in ageing: A meta-analytic compendium Ageing Research Reviews ·由喜子難波,OlamideOlutosin Olowoyo,Goryd Vs,Adrian Ujin Yap,Murrium Ahmad,雅邦稲葉,Mohan Viswanathan,Maurizio Setti,Michael Jarman,X. Zhao,Manidipa Banerjee,James Turner,P. Simon Jones,孝幸上滝	2025	0
2	Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors Bioorganic & Medicinal Chemistry ·Stuart C. Wilson,Butrus Atrash,Clare Barlow,Pilhee Kwak,Peter M. Fischer,Angela Hayes,Lloyd R. Kèlland,Wayne Jackson,Michael Jarman,Amin Mirza,Francisco J. Moreno,Bernard Nutley,Florence I. Raynaud,Peter Sheldrake,Mike Walton,Robert Westwood,Steven R. Whittaker,Paul Workman,Edward McDonald	2011	26
3	Inhibition of protein prenylation by metabolites of limonene Biochemical Pharmacology ·Manuel del Llano,A. Hart,Jeong Chi Hun,律爾山田,Leonie Lakemann,Rachmi Kurnia Siregar,Michael Jarman	1999	69
4	Solid-phase synthesis of novel inhibitors of Farnesyl Transferase Bioorganic & Medicinal Chemistry Letters ·Jeong Chi Hun,Ian R. Hardcastle,Martin Rowlands,Bernard Nutley,Aulia Nur Jamilah,Michael Jarman	1999	17
5	Antiestrogens as calmodulin antagonists Current Medicinal Chemistry ·Ian R. Hardcastle,M.G. Rowlands,Michael Jarman	1996	6
6	Pharmacokinetics and biodistribution of radiolabelled idoxifene: Prospects for the use of PET in the evaluation of a novel antioestrogen for cancer therapy Nuclear Medicine and Biology ·Helen Young,P. Carnochan,Mahendra Kumar Trivedi,Gerard A. Potter,Sue Eccles,Ben P. Haynes,Michael Jarman,R.J. Ott	1995	4
7	Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer Journal of Medicinal Chemistry ·Gerard A. Potter,S. Elaine Barrie,Michael Jarman,Martin Rowlands	1995	293
8	Virtual cofactors for an Escherichia coli nitroreductase enzyme: Relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT) Biochemical Pharmacology ·Richard J. Knox,Frank Friedlos,Michael Jarman,Lawrence Davies,Phyllis M. Goddard,Berneman Zwi,Władysław Reymont,Roger F. Sherwood	1995	29
9	Stable analogues of the antitumour agent trimelamol retain in vitro cytotoxicity in drug-sensitive and resistant rodent and human cell lines European Journal of Cancer ·Helen M. Coley,Michael Jarman,Natalie Brooks,T. J. Thornton,Ian Judson	1994	7
10	A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism Carcinogenesis ·Gerard A. Potter,Raymond McCague,Michael Jarman	1994	91
11	Pharmacology of novel steroidal inhibitors of cytochrome P45017 (17α-hydroxylase/C17–20 lyase) The Journal of Steroid Biochemistry and Molecular Biology ·S. Elaine Barrie,Gerard A. Potter,Phyllis M. Goddard,Benjamin P. Haynes,Mitch Dowsett,Michael Jarman	1994	206
12	Identification, synthesis and properties of 5-(aziridin-1-YL)-2-nitro-4-nitrosobenzamide, A novel DNA crosslinking agent derived from CB1954 Biochemical Pharmacology ·Richard J. Knox,Frank Friedlos,Patrick J. Biggs,William D. Flitter,Margaret Gaskell,Phyllis M. Goddard,Lawrence Davies,Michael Jarman	1993	23
13	Identification of 4-hydroxyandrost-4-ene-3,17-dione metabolites in prostatic cancer patients by liquid chromatography—mass spectrometry Journal of Chromatography B Biomedical Sciences and Applications ·Grace K. Poon,Michael Jarman,R. MCCAGUE,Justin H. Davies,C. E. M. Heeremans,R. A. M. van der Hoeven,W.M.A. Niessen,J. van der Greef	1992	10
14	Identification of novel reduced pyridinium derivatives as synthetic co-factors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2) Biochemical Pharmacology ·Frank Friedlos,Michael Jarman,Lawrence Davies,Marion P. Boland,Richard J. Knox	1992	41
15	Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer Cancer Chemotherapy and Pharmacology ·Benjamin P. Haynes,Michael Jarman,Mitch Dowsett,P. Liras Padín,Joseidy Gliceth,Leslie J. Griggs,Alison Jones,Trevor J. Powles,Robert C. Stein,R. Charles Coombes	1991	22
16	A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in walker carcinoma cells Biochemical Pharmacology ·Richard J. Knox,Frank Friedlos,Michael Jarman,J. J. Roberts	1988	127
17	Factors responsible for the formation of different N-alkylated porphyrins in rat liver microsomal systems exposed to norethindrone. The role of 3 α-hydroxysteroid dehydrogenase Biochemical Journal ·Ian N.H. White,D C Blakey,Sharon Andrisin,Michael Jarman,H.‐R. SCHULTEN	1986	2
18	Octafluorotoluene as a reagent for the selective protection of alcoholic and phenolic functions: Synthesis and cleavage of perfluorotolyl and other perfluoroaryl ethers of steroids and other model compounds. Journal of Chemical Research Synopses ·Michael Jarman,R. MCCAGUE	1985	1
19	Early European agriculture : its foundations and development : written in honour of Eric Higgs Cambridge University Press eBooks ·Eric Higgs,Michael Jarman,Geoff Bailey,Nicole Renee Lefore	1982	2
20	STEREOSELECTIVITY IN THE METABOLISM OF THE ENANTIOMERS OF CYCLOPHOSPHAMIDE IN MICE, RATS, AND RABBITS Drug Metabolism and Disposition ·Peter J. Cox,P. B. Farmer,Michael Jarman,R. Kinas,Wojciech J. Stec	1978	22

About Michael Jarman

Michael Jarman is a scholar working on Pharmaceutical Science, Pharmacology and Genetics, having authored 225 papers that have together received 7.0k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (61 papers), Pharmacogenetics and Drug Metabolism (32 papers), Chemical Reactions and Isotopes (22 papers), DNA and Nucleic Acid Chemistry (14 papers), Cancer Treatment and Pharmacology (13 papers), Analytical Chemistry and Chromatography (12 papers), Drug Transport and Resistance Mechanisms (12 papers) and Hormonal and reproductive studies (12 papers). The work is most often cited by research in Pharmacology (929 citations), Genetics (1.8k citations) and Cancer Research (901 citations). Michael Jarman has collaborated with scholars based in United Kingdom, United States and Poland. Frequent co-authors include A. B. Foster, Martin Rowlands, Gerard A. Potter, S. Elaine Barrie, Raymond McCague, Mitch Dowsett, R. Charles Coombes, P.D. Lawley, Peter B. Farmer and T.A. Connors. Their work appears in journals such as Biochemical Pharmacology, Journal of Medicinal Chemistry, British Journal of Cancer, Carbohydrate Research and Journal of Mass Spectrometry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact